Leishmaniasis in humans: drug or vaccine therapy?

M Ghorbani, R Farhoudi - Drug design, development and therapy, 2017 - Taylor & Francis
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …

Vaccines for visceral leishmaniasis: A review

K Jain, NK Jain - Journal of immunological methods, 2015 - Elsevier
Visceral leishmaniasis, which is also known as Kala-Azar, is one of the most severely
neglected tropical diseases recognized by the World Health Organization (WHO). The threat …

Vaccines to prevent leishmaniasis

R Kumar, C Engwerda - Clinical & translational immunology, 2014 - Wiley Online Library
Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations
affecting people in tropical and subtropical regions of the world. Epidemiological and …

Leishmania treatment and prevention: Natural and synthesized drugs

AA Bekhit, E El-Agroudy, A Helmy, TM Ibrahim… - European journal of …, 2018 - Elsevier
Leishmaniasis affects over 150 million people all over the world, especially in subtropical
regions. Currently used antileishmanial synthesized drugs are associated with some …

Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel vaccine candidates and therapeutic targets

D Kumari, S Mahajan, P Kour, K Singh - Life sciences, 2022 - Elsevier
Leishmaniasis is a neglected tropical disease and remains a global concern for healthcare.
It is caused by an opportunistic protozoan parasite belonging to the genus Leishmania and …

Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins

M Agallou, E Athanasiou, O Koutsoni… - Frontiers in …, 2014 - frontiersin.org
Leishmaniasis is a significant worldwide health problem for which no vaccine exists.
Activation of CD4+ and CD8+ T cells is crucial for the generation of protective immunity …

A recombinant chimeric protein-based vaccine containing T-cell epitopes from amastigote proteins and combined with distinct adjuvants, induces immunogenicity and …

DP Lage, DL Vale, FP Linhares, CS Freitas… - Vaccines, 2022 - mdpi.com
Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL),
a potentially fatal disease caused by infection with Leishmania parasites. In the current …

Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases

G Volpedo, L Costa, N Ryan, G Halsey… - Journal of Venomous …, 2019 - SciELO Brasil
Abstract Neglected Tropical Diseases (NTDs) comprise of a group of seventeen infectious
conditions endemic in many developing countries. Among these diseases are three of …

Visceral leishmaniasis: an overview of vaccine adjuvants and their applications

S Ratnapriya, AA Sahasrabuddhe, A Dube - Vaccine, 2019 - Elsevier
Although there has been an extensive research on vaccine development over the last
decade and some vaccines have been commercialized for canine visceral leishmaniasis …

Insights into Leishmania Molecules and Their Potential Contribution to the Virulence of the Parasite

EK Elmahallawy, AAM Alkhaldi - Veterinary Sciences, 2021 - mdpi.com
Neglected parasitic diseases affect millions of people worldwide, resulting in high morbidity
and mortality. Among other parasitic diseases, leishmaniasis remains an important public …